QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that data from the company’s Phase 1 proof-of-mechanism clinical trial of QRL-101, a potentially best-in-class selective Kv7.2/7.3 ion channel opener, were selected for a poster presentation at the American Epilepsy Society (AES) 2025 Annual Meeting being held December 5-9, 2025 in Atlanta, GA.
Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of both neuronal excitability and membrane potential. QurAlis is currently planning a Phase 2 clinical trial to explore the effects of QRL-101 in developmental and epileptic encephalopathies (DEE). Preclinical studies have demonstrated that QRL-101 is more potent and exhibits the potential for fewer clinical adverse events that ezogabine, a less selective, first-generation, Kv7.2/7.3 channel opener. QurAlis is also advancing QRL-101 in amyotrophic lateral sclerosis (ALS).
QRL-101-05 (NCT06681441) was a randomized, double-blind, placebo-controlled, three-way crossover clinical trial of QRL-101 in healthy volunteers designed to understand the pharmacokinetic and dynamic relationship between QRL-101 and implicated electrophysiological markers for hyperexcitability in both cortical and peripheral neurons to support future development in epilepsy and ALS. The study shows evidence of brain penetration, target engagement, and potential anti-seizure effects demonstrated through biomarkers for transcranial magnetic stimulation electromyography (TMS-EMG) and electroencephalography (EEG).
The poster presentation details are below. Abstracts can be found on the AES website at www.aesnet.org.
Title: QRL-101-05: A Phase 1 Study to Evaluate Cortical and Motor Nerve Excitability in Healthy Volunteers Following Administration of the Kv7.2/7.3 Modulator QRL-101
Abstract and Poster Number: 3.504
Poster Session: Poster Session 3
Date/Time: Monday, December 8, 2025, 12:00-1:45PM ET
Location: Georgia World Congress Center Hall B2, Level 1
The QRL-101-05 study was conducted at the Centre for Human Drug Research, an early phase Contract Research Organization based in Leiden, The Netherlands.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251202434479/en/
Contacts
Media contact:
Kathy Vincent
kathy@kathyvincent.com
310-403-8951